Migraine attack treatment: A tailor-made suit, not one size fits all

Recent Patents on CNS Drug Discovery

Volumn 9, Issue 1, 2014, Pages 26-40

  Belvís, Robert ^a   Mas, Natalia ^a   Aceituno, Azahara ^a  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Analgesics; Ergot alkaloids; Migraine attack; NSAIDs; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALNIDITAN; ANALGESIC AGENT; AVITRIPTAN; DICLOFENAC; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE MESILATE; DONITRIPTAN; ELETRIPTAN; ERGOT ALKALOID; ETODOLAC; FROVATRIPTAN; IBUPROFEN; KETOPROFEN; KETOROLAC TROMETAMOL; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; VASODILATOR AGENT;

ANALGESIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC DAILY HEADACHE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH CARE COST; HUMAN; LIFESTYLE; MEDICAL CARE; MEDICAL HISTORY; MIGRAINE; PAIN INTENSITY; PAIN PARAMETERS; PHARMACODYNAMICS; PHARMACOKINETICS; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RECURRENT DISEASE; TABLET FORMULATION; TRANSFORMED MIGRAINE; ANIMAL; HABIT; MIGRAINE DISORDERS; PATENT; PSYCHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HABITS; HUMANS; LIFE STYLE; MIGRAINE DISORDERS; PATENTS AS TOPIC; QUALITY OF LIFE; VASODILATOR AGENTS;

EID: 84900564592     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889809666140307115100     Document Type: Article

References (225)

1. Goadsby PT, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. New England J Med 2002; 346: 257-70.
2. The InternationalClassification of Headache Disorders, 3rd edition (beta version). Headache Classification Committee of the International Headache Society (IHS). Cephalalgia 2013; 33(9): 629-808.
3. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurol 2009; 72 (5Suppl): s3-7.
4. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-9.
5. Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurol 1992; 42: 1225-31.
6. Lipton RB, Stewart WF, von Korff M. Burden of migraine: Societal costs and therapeutic opportunities. Neurol 1997; 48(suppl 5): S4-9.
7. Fox AW, Davis RL. Migraine chronobiology. Headache 1998; 38: 436-41.
8. Hamelsky SW, Stewart WF, Lipton RB. Epidemiology of migraine. Curr Pain Headache Reports 2001; 5: 189-94.
9. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41: 646-57.
10. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001(17 Suppl 1): S4-S12.
11. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan. Evaluation survey. Headache 2003; 43: 19-26.
12. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol 2006; 13: 333-45.
13. Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. Lifting the burden: the first 7 years. J Headache Pain 2010; 11: 451-5.
14. Atlas of headache disorders and resources in the world 2011. A collaborative project of World Health Organization and Lifting The Burden. WHO Library Cataloguing-in-Publication Data. Trento, Italy 2011.
15. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2163-2196.
16. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999; 159: 813-8.
17. Auray JP. Socio-economic impact of migraine and headaches in France. CNS Drugs 2006; 20: 37-46.
18. Stewart WF, Wood GC, Razzaghi H, Reed ML, Lipton RB. Work impact of migraine headaches. J Occup Environ Med 2008; 50: 736-45.
19. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008; 48: 553-63.
20. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2000; 55: 754-763.
21. Members of the task force: Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006; 13: 560-572.
22. Belvís R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009; 4(1): 70-81.
23. Göbel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: A double-blind, placebo-controlled, randomized study. Cephalalgia 2004; 24: 888-93.
24. Tulunay FC, Ergun H, Gulmez SE, Ozbenli T, Ozmenolu M, Boz C, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: A double-blind, cross-over, randomized, placebocontrolled, multi-center study. Functional Neurol 2004; 19: 197-202.
25. Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a doubleblind, randomized, controlled, parallel-group study. Headache 1998; 38: 201-7.
26. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebocontrolled, population-based study. Arch Internal Med 2000; 160: 3486-92.
27. Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain-Three double-blind, randomized, placebo-controlled trials. Arch of Neurol 1998; 55: 210-7.
28. Diener H, Pfaffenrath V, Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: A multicentre, randomized, double-blind, single-dose, placebocontrolled parallel group study. Cephalalgia 2005; 25: 776-87.
29. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, doubleblind, randomized, parallel-group, single-dose, placebocontrolled study. Headache 2006; 46: 444-53.
30. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: A multicentre doubleblind placebocontrolled study. Cephalalgia 1994; 14: 297-300.
31. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in selfmedication of mild to moderate headache: A comparison with acetylsalicylic acid and placebo. Cephalalgia 1995; 15: 531-5.
32. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-6.
33. Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24: 947-54.
34. Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane 2010; (4): CD008041.
35. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985; 5: 5-10.
36. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992; 32: 280-2.
37. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.Headache. 2010; 50(5): 808-18
38. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with Diclofenac sodium: A double-blind study. Headache 1992; 32: 98-100.
39. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13: 117-23.
40. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999; 9: 232-40.
41. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2012; 2: CD008783.
42. Havanka-Kanniainen H. Treatment of acute migraine attack: Ibuprofen and placebo compared. Headache 1989; 29: 507-9.
43. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12: 169-71.
44. Suthisisang C, Poolsup N, Kittikulsuth W, Pudchakan P, Wiwatpanich P. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother 2007; 41: 1782-91.
45. Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane 2010; (10): CD008039.
46. Allais G, De Lorenzo C, Airola G, Peano S, Benedetto C. Dexketoprofen trometamol in the treatment of acute migraine attack. Minerva Med 2000; 91: 153-9.
47. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003; 21: 173-5.
48. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: An Update. Pharm 2010; 3(1): 10-8.
49. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.Headache 2008; 48(8): 1157-68.
50. Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010; 30(11): 1336-45
51. Pfaffenrath V, Fenzl E, Bregman D, Färkkila M. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012; 32(10): 766-77.
52. A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
53. Oztürk V, Erta M, Baykan B, Sirin H, Ozge A; The Mig-Etol Study Group. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: A Randomized, Double-blind, Crossover, Multicenter, Phase III Clinical Trial. PainPract. 2012.
54. A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
55. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, doubleblind comparison of sumatriptan in the acute treatment of migraine.Eur Neurol 1991; 31: 314-22.
56. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003; 49: 20-9.
57. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47: 99-107.
58. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009; 49(6): 826-37.
59. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache 2011; 51(4): 507-17.
60. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990; 600: 587-98.
61. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-90.
62. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; 3: CD002915.
63. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther 2005; 27: 85-1794.
64. Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache 2007; 47: 1152-68.
65. Diamond M, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: Primary care for excedrin nonresponders. Headache 2004; 44: 209-16.
66. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: Implications for the selectiveantimigraine action of triptans. J Neurosci 2003; 23: 10988-97.
67. Wotherspoon G, Priestley JV. Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells. Neurosci 2000; 95: 465-71.
68. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning Pv, Larsson HB, et al. Evidence for a vascular factor in migraine. Ann Neurol 2011; 69: 635-45.
69. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci USA 2004; 101:4274-9.
70. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59: 1084-8.
71. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-58.
72. Gladstone JP, Dodick DW. Acute migraine: Which Triptan? Practical Neurol 2004; 4: 6-19.
73. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, et al. International headache society clinical trials subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia 2000; 20: 765-86.
74. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554-60.
75. Mathew NT. Naratriptan: A review. Expert Opin Investig Drugs 1999; 8: 687-95.
76. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: A review of its use in migraine. Drugs 1999; 58: 347-74.
77. Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database Syst Rev 2001; 3: CD003221.
78. Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev 2001; 3: CD003224.
79. Dowson AJ, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002; 3: 993-1005.
80. Keam SJ, Goa KL, Figgitt DP. Almotriptan: A review of its use in migraine. Drugs 2002; 62: 387-414.
81. Pascual J. A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. Expert Opin Pharmacother 2004; 5: 669-77.
82. Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: Meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2004; 13: 73-82.
83. Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: Systematic review of randomized controlled trials. J Clin Pharm Ther 2005; 30: 521-32.
84. McCormack PL, Keating GM. Eletriptan: A review of its use in the acute treatment of migraine. Drugs 2006; 66: 1129-49.
85. Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother 2007; 8: 3029-33.
86. Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007; 47: 1169-77.
87. Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008; 48: 236-47.
88. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001; 358: 1668-75.
89. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, et al. Subcutaneous Sumatriptan during the migraine aura. Neurol 1994; 44: 1587-92.
90. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11: 671-7.
91. Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, et al. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-8.
92. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43: 376-88.
93. Tepper SJ, Rapoport AM. The triptans: A summary. CNS Drugs 1999; 12: 403-17.
94. Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005; 27: 407-417.
95. Loder E, Brandes JL, Silberstein S, Skobieranda F, Bohidar N, Wang L, et al. Rizatriptan Protocol 060 Study Group. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache 2001; 41: 745-53.
96. Cady R, Crawford G, Ahrens S, Hairwassers D, Getson A, Visser WH, et al. Rizatriptan-RPD Study Group.Long-term efficacy and tolerability of rizatriptan wafers in migraine. Med Gen Med 2001; 3: 1.
97. Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 101-6.
98. Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int J Clin Pract 2003; 57: 573-6.
99. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 2004; 18: 1133-41.
100. Allen C. Rizatriptan: Clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: Novel drugs for migraine. New York: Oxford University Press, 2001; 199-205.
101. Prasanna D, Manoranjan S. Formulation and evaluation of fast dissolving films of zolmitriptan. Int Res J Pharm 2012; 3(5): 373-6.
102. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with subcutaneous sumatriptan: First placebo-controlled study. The Subcutaneous Sumatriptan-International Study Group. Cephalalgia 1992; 12: 308-13.
103. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-8.
104. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New England J Med 1991; 325: 316-21.
105. Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009; 49(10): 1435-44.
106. Cady RK, Aurora SK, Brandes JL, Rothrock JF, Myers JA, Fox AW, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011; 51(8): 1202-11
107. Rothrock JF, Cady RK, Aurora SK, Brandes JL, Myers JA, Fox AW, et al. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin 2011; 27(11): 2185-91.
108. Brandes JL, Rothrock JF, Cady RK, Aurora SK, Myers JA, Fox AW, et al. Multiple-attack efficacy and tolerability sumaveldoseproTM (needle-free subcutaneous sumatriptan) among current triptan users. Presented at the 15th Congress of the International Headache Society: June 23-26 2011; Berlin.
109. Rothrock JF, Cady RK, Aurora SK, Brandes JL, Myers JA, Fox AW, et al. Current triptan users requiring a change in migraine therapy demonstrated improved treatment satisfaction and confidence after trying sumavel-doseproTM (needle-free subcutaneous sumatriptan). Presented at the 15Th Congress of the International Headache Society: June 23-26 2011; Berlin.
110. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, doubleblind, placebo-controlled, dose-ranging study versus Zolmitriptan tablet. CNS Drugs 2003; 17: 653-67.
111. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebocontrolled study. CNS Drugs 2005; 19: 125-36.
112. Pascual J, Navarro A, Caminero AB, Jurado C, Díaz-Insa S, Huerta M. Symptomatic treatment of migraine with zolmitriptan: Experience with 82 patients. Neurologia 2006; 21: 188-91.
113. Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006; 46: 138-49.
114. Bellavance A, Belsey J. Triptan preference in acute migraine management: A retrospective review of patient records from a Canadian clinic population. Headache Care 2006; 3: 39-43.
115. Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000 7(Suppl 3): 82.
116. Luthringer R, Djupesland PG, Sheldrake CD, Flint A, Boeijinga P, Danjou P, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 2009; 61(9): 1219-28.
117. Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia 2010; 30(8): 933-42.
118. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009; 49(6): 817-25.
119. Schulman E, O'Neill C, Pierce M, Griesser J, Angelov A.S. Efficacy of Zelrix, a novel iontophoretic transdermal sumatriptan patch, in the treatment of acute migraine in patients with nausea. Presented at the 62nd Annual Meeting of the American Academy of Neurology; April 10-17, 2010; Toronto.
120. Smith T, Pierce M, Griesser J. An open-label study to evaluate the long-term safety of zelrixTM, a sumatriptan iontophoretic patch for the treatment of acute migraine. Presented at the 15Th Congress of the International Headache Society: June 23-26, 2011; Berlin.
121. Calatayud-Pascual MA, Balaguer-Fernández C, Serna-Jiménez CE, Del Rio-Sancho S, Femenía-Font A, Merino V, et al. Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011; 416(1): 189-94.
122. Dilone E, Bergstrom D, Cabana B, Nedumpara M, Fox AW; Sumatriptan Lingual Spray Study Group. Sumatriptan Lingual Spray Study Group. Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Headache 2009; 49(10): 1445-53.
123. Tepper SJ, Cochran A, Hobbs S, Woessner M. Sumatriptan suppositories for the acute treatment of migraine.Int J Clin Pract 1998; 52: 31-5.
124. Bertin L, Brion N, Färkkilä M, Göbel H, Wessely P. A dose defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 1999; 53: 593-8.
125. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2: CD009665.
126. Feleppa M, Apice G, D'Alessio A, Fucci S, Bigal ME. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia 2008; 28(10): 1012-6.
127. Jamieson DG.The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112: 135-40.
128. Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000; 40: 521-7.
129. Hall G, Brown M, Mo J, MacRae KD. Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurol 2004; 62: 563-8.
130. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44: 642-51.
131. Dahlöf CG, Mathew N. Cardiovascular safety of 5HT1B/1D agonists is there a cause for concern? Cephalalgia 1998; 18: 539-45.
132. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: A two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554-9.
133. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998; 18: 532-8.
134. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993; 33(7): 385-9.
135. Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23(3): 197-205.
136. Lance JW, Anthony M. Some clinical aspects of migraine. A prospective survey of 500 patients. Arch Neurol 1966; 15(4): 356-61.
137. Somerville BW. A study of migraine in pregnancy. Neurol 1972; 22(8): 824-8.
138. Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache.1999; 39(9): 625-632.
139. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-4.
140. Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351-6.
141. Bánhidy F, Acs N, Horváth-Puhó E, Czeizel AE. Maternal severe migraine and risk of congenital limb deficiencies. Birth Defects Res A Clin Mol Teratol 2006; 76(8): 592-601.
142. Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache 2009; 49(10): 1414-22.
143. Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia. 2005; 25(9): 685-8.
144. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159-63.
145. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings EL. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42(1): 8-15.
146. Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache 2010; 50(4): 563-75.
147. Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, et al. Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidmiologic study. Clinical Neuropharmacol 1999; 22: 201-6.
148. Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. Lancet 1999; 353: 78.
149. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurol 2001; 57: 1694-8.
150. Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia 2013; 33(11): 891-6
151. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment.Headache 2003; 43(1): 36-43.
152. Brandes JL. Treatment approaches to maximizing therapeutic response in migraine. Neurol 2003; 61: S21-26.
153. Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45(5): 538-45.
154. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47(5): 614-24
155. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache.2000; 40(10): 792-7.
156. Dodik DW. Triptan Nonresponder Studies: Implications for clinical practice. Headache 2005; 45: 156-62
157. Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L, et al. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migrainefree period. Cephalalgia 1996; 16: 270-5.
158. Tfelt-Hansen P, Edvinsson L. Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment. Cephalalgia 2007; 27: 1091-3.
159. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 543-8.
160. Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997; 43: 579-87.
161. Brandes JL, Kudrow D, Stark SR, Frishberg BM, Alexander WJ, Zhang Y, et al. Sumatriptan-naproxen for acute treatment of migraine. JAMA 2007; 297: 1443-54.
162. Winner P, Cady RK, Ruoff GE, Frishberg BM, Alexander WJ, Zhang Y, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc 2007; 82: 61-8.
163. Smith T, Blumenthal H, Diamond M, Mauskop A, Ames M, McDonald S, et al. Sumatriptan/Naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes. Headache 2007; 47: 683-92.
164. Krymchantowski AV, Jevoux CDA.The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migraine-a review. Recent Patents CNS Drug Discov 2007; 2: 141-4.
165. Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurol 2008; 71: 114-21.
166. Landy S, White J, Lener SE, McDonald SA. Fixed-dose sumatriptan/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free/no adverse events. Ther Adv Neurol Disord 2009; 2(3): 135-41.
167. Landy S, DeRossett SE, Rapoport A, Rothrock J, Ames MH, McDonald SA, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: Function, productivity, and satisfaction outcomes. Med Gen Med 2007; 9: 53.
168. Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, et al. Fixed-dosesumatriptan and naproxen in poorresponders to triptans with a shorthalf-life. Headache 2009; 49(7): 971-82.
169. Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine. In: Clinical Trials. Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
170. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophenalone for acute migraine treatment. Headache 2008; 48: 921-30.
171. Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 2006; 26: 871-4.
172. Krymchantowski, A.V. Pharmaceutical combinations for the treatment of head-aches and migraine attacks as well as blisters and packs that contain them. US20080081798A1 (2008).
173. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004; 4: 10.
174. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs rizatriptan for the acute treatment of migraine: An open label pilot study. Cephalalgia 2002; 22: 309-12.
175. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43: 729-33.
176. Maichle, W.R., Whatley, C.L., Reiner, G., Reiner, A. Fixed combination dosage forms for the treatment of migraine. WO2007127207A2 (2007).
177. Goldstein J, Dahlöf CG, Diener HC, Olesen J, Schellens R, Senard JM, et al. Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. Cephalalgia 1996; 16: 497-502
178. Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlöf C, et al. The efficacy and safety of sc alniditan vs sc sumatriptan in the acute treatment of migraine: A randomized, double-blind, placebocontrolled trial. Cephalalgia 2005; 21: 672-9.
179. Knight YE, Edvinsson L, Goadsby PJ. Blockade of calcitonin generelated peptide release after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122, 288. Neuropeptides 1999; 33: 41-6.
180. Sharma A, Jusko WJ, Fulmor IE, Norton J, Uderman HD, Salazar DE. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects. J Clin Pharmacol 1999; 39: 685-94.
181. Muñoz-Islas E, Gupta S, Jiménez-Mena LR, Lozano-Cuenca J, Sánchez-López A, Centurión D, et al. Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Br J Pharmacol 2006; 149: 82-91.
182. Létienne R, Blanchet JC, Sole E, John GW, Le Grand B. Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: An overlooked mechanism of antimigraine action? J Pharmacol Exp Ther 2005; 315: 849-57.
183. Lantéri-Minet M, Massiou H, Romatet S, Barba A, Lucas C, Allaf B. An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study). Headache 2011; 51(4): 590-601.
184. Nijjar SS, Pink L, Gordon AS. Examination of migraine management in emergency departments. Pain Res Manag 2001; 16(3): 183-6.
185. Mateos V, Diaz-Insa SI, Morera J, et al. Action plan against migraine (PALM). Migraine management in neurology clinics in Spain. Neurologia 2007; 3 (4): 7-14.
186. Steiner TJ, Catarci T, Hering R, Whitmarsh T, Couturier EG. If migraine prophylaxis does not work, think about compliance. Cephalalgia 1994; 14(6): 463-4.
187. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1998; 18(1): 52-6.
188. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia 2003; 23(4): 293-301.
189. Rains JC, Penzien DB, Lipchik GL. Behavioral facilitation of medical treatment for headache--part II: Theoretical models and behavioral strategies for improving adherence. Headache 2006; 46(9): 1395-403.
190. Linde M, Jonsson P, Hedenrud T. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand 2008; 118(6): 367-72.
191. Hedenrud T, Jonsson P, Linde M. Beliefs about medicines and adherence among Swedish migraineurs. Ann Pharmacother 2008; 42(1): 39-45.
192. Evans RW, Linde M. Expert opinion: adherence to prophylactic migraine medication. Headache 2009; 49(7): 1054-8.
193. Lafata JE, Tunceli O, Cerghet M, Sharma KP, Lipton RB. The use of migraine preventive medications among patients with and without migraine headaches.Cephalalgia 2010; 30(1): 97-104.
194. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350(11): 1104-10.
195. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. MK-0974 Protocol 004 Study Group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurol 2008; 70(16): 1304-12.
196. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebocontrolled, paralleltreatment trial. Lancet 2008; 372(9656): 2115-23.
197. Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurol 2009; 73(12): 970-7.
198. Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010; 30(12): 1443-57.
199. Tfelt-Hansen P. Is the dose-response of telcegepant well characterized? Presented at the 15Th Congress of the International Headache Society: June 23-26, 2011; Berlin.
200. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31(6): 712-22.
201. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011; 31(5): 573-84.
202. Tong G, Savant I, Jariwala N, Burt D, Zheng, N, Buzescu A, et al. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. Presented at the 3rd European Headache and Migraine Trust International Congress of the Migraine Trust and European Headache Federation; Setember 20-23, 2012; London.
203. Bowler KE, Worsley MA, Broad L, Sher E, Benschop R, Johnson K, et al. Evidence for anti-inflammatory and putative analgesic effects of a monoclonal antibody to calcitonin gene-related peptide. Neurosci 2012; S0306-4522(12): 1045-7.
204. Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 2007; 567(1-2): 117-24.
205. Shi L, Rao S, Sun H, Wild K, Xu C. In vitro characterization of AA71, a potent and selective human monoclonal antibody against CGRP receptor. Presented at the 3rd European Headache and Migraine Trust International Congress of the Migraine Trust and European Headache Federation; Setember 20-23, 2012; London.
206. Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. European COL-144 Investigators.Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia 2010; 30(10): 1170-8.
207. Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, et al. COL MIG-202 Study Group. Efficacy and tolerability of lasmiditan, an oral 5-HT (1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11(5): 405-13.
208. Medve RA, Lategan TW. A phase 2 multicenter, randomized, double-blind, parallelgroup, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura. Presented at the 2rd European Headache and Migraine Trust International Congress of the Migraine Trust and European Headache Federation; October 28-31 2010; Nice.
209. Hougaard A, Hauge AW, Guo S, Olesen J. NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Presented at the 15Th Congress of the International Headache Society: June 23-26, 2011; Berlin.
210. Study of NXN 188 for the treatment of migraine with aura. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health [online]. Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
211. Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009; 49(3): 281-90.
212. Adaptive design trial of GW274150 in the treatment of acute migraine. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Avalaible at: http://clinicaltrials.gov/. Accesed October 11, 2013.
213. Silberstein SD, Schoenen J, Göbel H, Diener HC, Elkind AH, Klapper JA, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia 2009; 29 Suppl 2: 17-27.
214. Dahlöf CG, Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia 2009; 29 Suppl 2: 7-16.
215. Kostic MA, Gutiérrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 2010; 56(1): 1-6.
216. Lambert GA, Davis JB, Appleby JM, Chizh BA, Hoskin KL, Zagami AS. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 2009; 380(4): 311-25.
217. Efficacy and safety of BGG492 in the treatment of migraine. In: http://clinicaltrials.gov/. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
218. A randomized, double blind, placebo controlled study to assess efficacy, safety and tolerability of BGG492 in migraine prevention. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
219. Double-blind, placebo-controlled study of BGC20-1531 in migraine. In: http://clinicaltrials.gov/. A service of the U.S. National Institutes of Health[online].Avalaible at: http://clinicaltrials.gov/. Accessed October 11, 2013.
220. Safety and efficacy of NPS 1776 in the acute treatment of migraine headaches. In: http://clinicaltrials.gov/. A service of the U.S. National Institutes of Health[online]. Avalaible at: http://clinicaltrials.gov/. Accessed October 11, 2013.
221. Nitrous oxide for acute migraine pain in the emergency room (ED). In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online]. Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
222. Normobaric oxygen (NBO) therapy in acute migraine. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
223. A double blind randomized controlled of placebo and nebulized lidocaine for migraine headache. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online]. Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
224. Study to evaluate the efficacy and safety of dronabinol metered dose inhaler (MDI) in acute treatment of migraine headache. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online].Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.
225. The effect of nasal carbon dioxide in the treatment of moderate to severe migraine. In: ClinicalTrials.Gov. A service of the U.S. National Institutes of Health[online]. Available at: http://clinicaltrials.gov/. Accessed October 11, 2013.